ABMD — Abiomed Share Price
Last trade - 00:00- $17.18bn
- $16.36bn
- $1.03bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 71.67 | ||
| PEG Ratio (f) | 6.12 | ||
| EPS Growth (f) | 13.26% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.16 | ||
| Price to Tang. Book | 12.13 | ||
| Price to Free Cashflow | 79.09 | ||
| Price to Sales | 16 | ||
| EV to EBITDA | 58.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.23% | ||
| Return on Equity | 18.24% | ||
| Operating Margin | 23.61% | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 593.75 | 769.43 | 840.88 | 847.52 | 1,031.75 | 1,145 | 1,327.68 | 18.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +149.64 | +92.65 | -19.61 | +9.43 | +4.81 | -12.66 | +24 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ABIOMED, Inc. is a medical technology provider, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The Company's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.
Directors
- Michael Minogue CHM (54)
- Todd Trapp CFO (50)
- David Weber COO (59)
- Marc Began VPR (54)
- Andrew Greenfield VPR (48)
- Dorothy Puhy LED (69)
- Paula Johnson IND (60)
- Jeannine Rivet IND (73)
- Myron Rolle IND (34)
- Eric Rose IND (70)
- Martin Sutter IND (66)
- Paul Thomas IND (65)
- Christopher Van Gorder IND (68)
- Last Annual
- March 31st, 2022
- Last Interim
- September 30th, 2022
- Incorporated
- June 4th, 1987
- Public Since
- July 29th, 1987
- No. of Shareholders
- 351
- No. of Employees
- 2,003
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 45,091,184
- Address
- 22 CHERRY HILL DR, DANVERS, 01923-2575
- Web
- https://www.abiomed.com/
- Phone
- +1 9787775410
- Auditors
- Deloitte & Touche LLP
Latest News for ABMD
Upcoming Events for ABMD
Q3 2023 ABIOMED Inc Earnings Release
Q4 2023 ABIOMED Inc Earnings Release
Similar to ABMD
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Acutus Medical
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
FAQ
As of Today at 18:00 UTC, shares in Abiomed are trading at $381.02. This share price information is delayed by 15 minutes.
Shares in Abiomed last closed at $381.02 and the price had moved by +14.7% over the past 365 days. In terms of relative price strength the Abiomed share price has outperformed the S&P500 Index by +42.93% over the past year.
The overall consensus recommendation for Abiomed is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Abiomed does not currently pay a dividend.
Abiomed does not currently pay a dividend.
Abiomed does not currently pay a dividend.
To buy shares in Abiomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $381.02, shares in Abiomed had a market capitalisation of $17.18bn.
Here are the trading details for Abiomed:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABMD
Based on an overall assessment of its quality, value and momentum Abiomed is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abiomed is $363.00. That is 4.73% below the last closing price of $381.02.
Analysts covering Abiomed currently have a consensus Earnings Per Share (EPS) forecast of $4.52 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abiomed. Over the past six months, its share price has outperformed the S&P500 Index by +51.38%.
As of the last closing price of $381.02, shares in Abiomed were trading +30.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abiomed PE ratio based on its reported earnings over the past 12 months is 71.67. The shares last closed at $381.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abiomed's management team is headed by:
- Michael Minogue - CHM
- Todd Trapp - CFO
- David Weber - COO
- Marc Began - VPR
- Andrew Greenfield - VPR
- Dorothy Puhy - LED
- Paula Johnson - IND
- Jeannine Rivet - IND
- Myron Rolle - IND
- Eric Rose - IND
- Martin Sutter - IND
- Paul Thomas - IND
- Christopher Van Gorder - IND